Evogene Ltd. · NASDAQ:EVGN
Evogene — Investor Presentation (February 2018)
38 slides from Evogene's investor presentation, Feb 12, 2018
Slide 1: Company Presentation, February 2018
Company PresentationFebruary, 2018 Ofer Haviv, President & CEO
Slide 2: Safe Harbor Statement
Safe Harbor Statement 2 This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or i
Slide 3: What We Do
What We Do 3 We develop novel products for life-science markets… …through the use of a unique Computational Predictive Biology (CPB) platform
Slide 4: Evogene at a Glance
Evogene at a Glance… 4 Commercial Partners Improved Seeds InnovativeAg-Chemicals NovelAg-Biologicals Geneticelements Microbes Chemical compounds CPB An innovative, Computationally Predictive Biology (CPB) platform - applied to identify:Genetic elements for improved seedsChemical compounds for innova
Slide 5: Strategic Collaborations Through the Years
Strategic Collaborations Through the Years 5
Slide 6: Evogene – An Evolving Story
Evogene – An Evolving Story 6 Seed TraitsYield & ABSTPlant Disease EvofuelCastor Seeds (100%) CPB IPO TASE - IPO NYSE2007-2013 GMO, Breeding
Slide 7: Evogene – An Evolving Story
Evogene – An Evolving Story 7 Ag BiologicalsBio Stimulants (100%) CPB Seed TraitsYield & ABSTPlant DiseaseInsect Control EvofuelCastor Seeds IPO NYSE – Sep 20172013-2017 GMO, Breeding Ag ChemicalsHerbicidesInsecticides
Slide 8: Evogene – An Evolving Story
Evogene – An Evolving Story 8 BiomicaHuman Microbiome based Therapeutics (100%) (90%) CPB GMO, Breeding,Genome Editing Seed TraitsYield & ABSTPlant DiseaseInsect Control EvofuelCastor Seeds Ag ChemicalsHerbicidesInsecticides Ag BiologicalsBio StimulantsBio Pesticides Sep 2017 - Onward2017 - Onward
Slide 9: Corporate Structure
Corporate Structure 9 Ag Divisions Seeds Biologicals Chemicals Subsidiaries Computational Predictive Biology Platform (CPB)
Slide 10: Evogene's Unique Product Development Approach
Evogene’s Unique Product Development Approach 10 Product Definition Successful Product Launch … Evogene takes product criteria into account at Stage Zerofocusing only on optimal product candidates The increasing number of criteria for successful product launch have made traditional linear methodolog
Slide 11: Computational Predictive Biology (CPB) Platform
Computational Predictive Biology (CPB) Platform Interconnected data hub Science: unique multidisciplinary scientific approach Tailored big data Analysis platforms using machine learning/AI to identify candidates Chemical discovery Stack discovery Target discovery Gene discovery Gene optimization Tox
Slide 12: Predictive Analysis Validation
12 Predictive Analysis Validation
Slide 13: Product Development
Product Development Revosene
Slide 14: Corporate Structure
Corporate Structure 14 Ag Divisions Seeds Biologicals Chemicals Subsidiaries Computational Predictive Biology Platform (CPB)
Slide 15: Ag Seeds – Market & Potential
Existing Biotech Traits Market Potential Biotech Traits Market Insect resistance Herbicide tolerance Yield Drought tolerance Disease resistance Corn $3.2B $3.5B $1.5B $0.65B $1B Soy $0.5B $1.5B $1.2B $0.45B $1B Ag Seeds - Market & Potential 15 Biotech Innovation Trait Potential * Source: Phillips Mc
Slide 16: Ag Seeds – Product & Technology
16 Ag Seeds – Product & Technology Stability Safety Via: Breeding, Genome Editing & GMO Improved Seed Traits The CPB platform - ‘Connecting the Dots’ Environment Efficacy The CPB platform - ‘Connecting the Dots’ Yield and environmental stress traits- Yield, drought, nitrogen usage efficiencyDisease
Slide 17: Genome Editing – New Promising Technology
Genome Editing – New Promising Technology 17 Evogene’s unique advantage – ‘What to edit’Technological capabilities, knowledge and proprietary plant genomics big data, allow the identification of required edit-targets for crop improvement Novel method for improving seed traitsResulting products may b
Slide 18: Ag Seeds Pipeline (main programs)
Corn Yield Drought Nitrogen use efficiency Fusarium stalk rot Insect control Coleop. Insect control Lepido. Soybean Yield Drought Asian Rust Insect control Lepido. Insect control Hemip. Cotton Insect control Lepido. Banana Black Sigatoka Ag Seeds Pipeline (main programs) Discovery Phase 1 (POC) Phas
Slide 19: Select Results - Black Sigatoka
Select Results - Black Sigatoka 19 8 Genes showed repeated increased resistance in two separate banana field trialsPositive results were observed with zero fumigationLeveraging validated genes with positive results to genome editing product development Banana with high resistance to the Black Sigato
Slide 20: Corporate Structure: Biologicals
Biologicals Corporate Structure 20 Ag Divisions Seeds Chemicals Subsidiaries Computational Predictive Biology Platform (CPB)
Slide 21: Ag Biologicals Market & Potential
21 Ag Biologicals Market & Potential ~$8B ~$3.2B Source – 2022 estimation based on integrated information of BCC Research, marketsandmarkets, Agropages and Phillips McDougall (2015) 2022 E Key market drivers Major Ag companies are getting in: New startups are emerging: Bio-Stimulants - 38% Bio-Pesti
Slide 22: Ag-Biologicals – Product & Technology
The CPB platform - ‘Connecting the Dots’ Ag-Biologicals – Product & Technology 22 Plant Pest Microbiome(plant/ pest) Bio-Stimulants & Bio-Pesticides Harnessing naturally occurring microbiome to develop:Bio-Stimulant seed treatments – targeting yield improvement in row crops such as corn, wheatBio-Pe
Slide 23: Ag-Biologicals Pipeline
Ag-Biologicals Pipeline 23 Discovery Early development Pre-Commercialization Bio Stimulants Corn Wheat Bio Pesticides Corn Root Worm Stinkbug (Soy) Lepidoptera(Specialty) Bio Fungicide Fusarium (Corn) Mildew (Grapes) Development 1 Development 2 Program Product *Timeline according to industry estimat
Slide 24: Select Results – Corn Bio-Stimulants
Select Results – Corn Bio-Stimulants 24 None - inoculated EVO004 Stem below ear R2 Stem below ear R2 Ear R3 Ear R3 14 1 16 1 Under moderate drought 10% Yield improvement in field trials (2016, 2017)
Slide 25: Corporate Structure: Chemicals
Corporate Structure 25 Ag Divisions Seeds Biologicals Chemicals Subsidiaries Computational Predictive Biology Platform (CPB)
Slide 26: Ag-Chemicals - Market & Potential
Ag-Chemicals - Market & Potential 26 Increasing weed resistance to leading herbicide - Glyphosate 2015 Source: Phillips McDougall** Sources: ‘Phillips McDougall’ and ‘Markets and Markets’, 2017 Insecticides Fungicides Herbicides Other ~$50B*Agro-Chemical Market(2016) Agro-Chemical Marketexpected to
Slide 27: Ag-Chemicals – Product & Technology
The CPB platform - ‘Connecting the Dots’ Herbicides & Insecticides Ag-Chemicals – Product & Technology 27 Delivery Chemistry Herbicides & Insecticides Plant/Insect Biology Novel Herbicides - inhibiting novel MoA (Mode-of-Action) Novel Insecticides - inhibiting novel SoA (Site-of-Action) within key n
Slide 28: Ag-Chemicals Pipeline
Ag-Chemicals Pipeline 28 2-3 yearsDiscovery 3-4 yearsPre-development 3-4 yearsDevelopment & Registration Herbicides Novel herbicides AI optimization New targets Novel herbicides Phase undisclosed Insecticides New SoA Program Target identification Computational Screen Hit Validation Hit-to-Lead Lead
Slide 29: Select Results – Novel Herbicides
Select Results – Novel Herbicides 29 Dosage Molecule Optimization Molecule Example of Efficacy Optimization of Chemical Compounds on Weeds (Y 2017) *Initial results before optimization Example for Chemical Compound - Displaying Herbicidal Activity in Greenhouse
Slide 30: Corporate Structure: Subsidiaries
Corporate Structure 30 Ag Divisions Seeds Biologicals Chemicals Subsidiaries Computational Predictive Biology Platform (CPB)
Slide 31: Evofuel
Evofuel 31 Mission: providing farmers with the most advanced castor seeds & ag-service solutions Evofuel targets South America Genomics & Technology- advanced breeding and varietiesSeed production- Castor bean fields for the production of seedsAgro-technical support- Market specific crop protocolsMe
Slide 32: Biomica
Biomica 32 Sources: BCC Research (2017) – Human Microbiome-based Drugs and Diagnostics Market. SVB – (Emerging Healthcare: Microbiome Investment Trends Aug 2017) ~$ 10Bn market opportunity by 2024 Mission: discovery and development of human microbiome based therapeutics $840M invested in microbiome
Slide 33: Corporate Structure
Corporate Structure 33 Ag Divisions Seeds Biologicals Chemicals Subsidiaries Computational Predictive Biology Platform (CPB)
Slide 34: Evogene Highlights
Evogene Highlights 5 2 3 4 Strong balance sheet 1 Engine for next generation product for life science - targeting multi-billion dollar markets Unique technology platform (CPB), combining expertise in life science and cutting-edge computational technology – ‘Connecting the Dots’ Diversified product p
Slide 35: Thank You
Thank You Contact:investors@evogene.comT: +972 8 931 1934
Slide 36: Appendix - Financials
Reve Appendix - Financials
Slide 37: Key Financials – Balance Sheet
Key Financials – Balance Sheet 37 Thousand US $ 30.9.2017 31.12.2016 Current Assets 77,842 89,490 Long-Term Assets 5,263 6,496 Total Assets 83,105 95,986 Current Liabilities 4,661 5,225 Long-Term Liabilities 3,439 3,472 Shareholders Equity 75,005 87,289 Total Liabilities & Shareholders Equity 83,105
Slide 38: Key Financials – P&L
Key Financials – P&L 38 Thousand US $ 9M 2017 9M 2016 2016 Revenues 2,647 5,360 6,540 Gross Profit 436 852 901 Operating Loss (15,928) (14,937) (21,089) Net Loss (14,614) (12,949) (19,592) Key Points: Revenues consist primarily of R&D revenues, reflecting cost reimbursement under our collaboration a